by EpicentRx | Jun 21, 2024 | Media
YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors The future of AdAPT-001 in patients...
by EpicentRx | Jun 21, 2024 | Media
by EpicentRx | Jun 14, 2024 | Conferences
November 5-7 , 2022 – McCormick Place, Chicago, IL View Poster
by EpicentRx | May 23, 2024 | 2024, Press Releases
Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them...
